A: Epidemiology update

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Global impact of ischemic heart disease World Heart Federation, 2011.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Introduction Lipoprotein(a) [Lp(a)]
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
DIABETES INSTITUTE JOURNAL CLUB CARINA SIGNORI, D.O., M.P.H. DECEMBER 15, 2011 Atherothrombosis intervention in metabolic syndrome with low HDL/High Triglycerides:
내과 R1 문정락 / prof. 정경환 N Engl J Med 369;10 nejm.org 932 september 5, 2013.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):
Data Sources Definitions
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.
Dyslipidemia after Kidney Transplant
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
What should the Systolic BP treatment goal be in patients with CKD?
Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,
The SPRINT Research Group
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
The role of unknown risk factors in coronary heart disease
Michael J. Koren, MD, Michael H. Davidson, MD, Daniel J
Should we move from Lipids to Lipoproteins, from Dyslipidemia to Dyslipoproteinemia in future guidelines for CVD?
Clinical need for determination of vulnerable plaques
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Alina M. Allen MD, Patrick S. Kamath MD, Joseph J. Larson,
Chapter 1: CKD in the General Population
Copyright © 2007 American Medical Association. All rights reserved.
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
The IDEAL Study Reference
AIM HIGH Niacin plus Statin to prevent vascular events
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
TNT: Baseline and final LDL cholesterol levels
Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Teaching Tool: Blood Pressure Classification
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Systolic Blood Pressure Intervention Trial (SPRINT)
The percentage of subjects with de novo development of renal function impairment (GFR
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
Baseline characteristics of HPS participants by prior diabetes
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Chapter 1: CKD in the General Population
Type 2 diabetes: Overlap of clinical conditions
Nationwide epidemic of obesity
Cardiovascular Disease and CKD: Core Curriculum 2010
Fellström BC, et al. N Engl J Med 2009;360:1455-7
به نام خدا.
I. Introduction American Journal of Kidney Diseases
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.
Correlation between endothelial function and hypertension
American Journal of Kidney Diseases
Goals & Guidelines A summary of international guidelines for CHD
Baseline Characteristics of the Subjects*
Section II: Lipid management
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
Presentation transcript:

A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Content points: Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were followed over a mean of 8 years for the occurrence of first CV events. These included nonfatal myocardial infarction (MI), nonfatal ischemic stroke, coronary revascularization procedures, and CV death.1 Kaplan-Meier survival curves are shown according to 4 groups, based on whether participants were above or below the median C-reactive protein (CRP) value (1.52 mg/L) and the median low-density lipoprotein cholesterol (LDL-C) value (123.7 mg/dL or 3.20 mmol/L). The results show that CRP and LDL-C are not strongly correlated, suggesting that they detect different high-risk groups. Evaluation of both CRP and LDL-C may be more predictive than either marker alone. CRP may be a stronger predictor than LDL-C: the high-CRP/low-LDL-C group had a lower probability of event-free survival than the low-CRP/high-LDL-C group. 1 Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.

1 in 4 adults have diabetes or the metabolic syndrome Content points: A 2001 survey of 195,000 US adults aged ≥18 revealed an overall 7.9% prevalence of diabetes, giving an estimated 18 million adults with diabetes in 2002.1 The highest prevalence of diabetes is seen in blacks (11.2%), followed by Hispanics (9.0%), “other” (8.2%), and whites (7.2%). In addition, the American Diabetes Association estimates that there may be as many as 8 million currently undiagnosed diabetics in the United States.2 The metabolic syndrome, a predisposing factor to development of diabetes and CV disease, has an overall prevalence in the US adult population of 23.7%. An estimated 47.7 million adults in this country are now affected.3 Hispanics show the highest rates of the metabolic syndrome, a 31.9% prevalence. Overall, diabetes or the metabolic syndrome is present in one out of four adults in the United States. 1 Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79. 2 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(suppl 1):S5-S20. 3 Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.

Low physical activity, 66% vs 56% Higher prevalence of CV risk factors in adults with vs without diabetes Content points: Estimates for CV disease risk factors were calculated from data on 9496 adults with diabetes and 105,493 adults without diabetes.1 Modifiable risk factors were more prevalent in adults with diabetes than without diabetes (P < 0.001): Hypertension, 56% vs 22% High cholesterol, 41% vs 20% Obesity, 78% vs 57% Low physical activity, 66% vs 56% 1 Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: Prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002;162:427-433.

Level of kidney function: An independent risk factor for CV disease Content points: Manjunath et al studied the relation between level of kidney function and risk of CV disease in a community cohort.1 Study subjects were enrolled in the Atherosclerotic Risk in Communities (ARIC) study, an ongoing, community-based longitudinal study of coronary heart disease and stroke. The present study included 15,350 subjects recruited from communities in Mississippi, North Carolina, Minnesota, and Maryland. Kidney function was assessed by glomerular filtration rate (GFR), which was estimated from serum creatinine values. Study subjects were stratified as follows: Normal kidney function: GFR 90 to 150 mL/min/1.73m2 Mild decrease in kidney function: GFR 60 to 89 mL/min/1.73m2 Moderate to severe decrease in kidney function: GFR 15 to 59 mL/min/1.73m2 As shown, Kaplan-Meier survival analysis showed a greater probability for CV disease in subjects with lower GFR during a mean follow-up of 6.2 years. The adjusted hazard ratio was 1.38 (95% CI, 1.02 to 1.87; P = 0.038) for the group with moderate to severe decrease in GFR versus the group with normal GFR. The findings from the ARIC study extend previous studies demonstrating an association between kidney function and CV risk in patients with CV disease or at high risk for CV disease. The ARIC results demonstrate that level of kidney function is an independent risk factor for CV disease in the community. 1 Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47-55.

Increased prevalence of dyslipidemia in patients with vs without chronic kidney disease Content points: The prevalence of dyslipidemia is increased in patients with chronic kidney disease (CKD) relative to the general population. However, the specific type and severity can vary depending on severity of chronic kidney disease.1 In chronic kidney disease without proteinuria, the lipid profile is similar to that observed in the metabolic syndrome, with elevated triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C), and minimally elevated LDL-C. However, patients with chronic kidney disease also have higher amounts of small, dense LDL-C (not shown) and lipoprotein (a) [Lp(a)] than the general population. In chronic kidney disease with proteinuria, LDL-C, triglycerides, and Lp(a) are elevated and HDL-C is decreased. Thus, patients with chronic kidney disease should be screened for dyslipidemia. 1 Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(suppl 3):S152-S156.